189 related articles for article (PubMed ID: 17084158)
1. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
Roach M; Weinberg V; Nash M; Sandler HM; McLaughlin PW; Kattan MW
J Urol; 2006 Dec; 176(6 Pt 2):S16-20. PubMed ID: 17084158
[TBL] [Abstract][Full Text] [Related]
2. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
3. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
4. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
8. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
10. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
11. Does age matter in the selection of treatment for men with early-stage prostate cancer?
Konski A; Eisenberg D; Horwitz E; Hanlon A; Pollack A; Hanks G
Cancer; 2006 Jun; 106(12):2598-602. PubMed ID: 16683224
[TBL] [Abstract][Full Text] [Related]
12. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
[TBL] [Abstract][Full Text] [Related]
14. [Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy].
Graefen M; Augustin H; Karakiewicz PI; Hammerer PG; Haese A; Palisaar J; Fernandez S; Noldus J; Erbersdobler A; Cagiannos I; Scardino PT; Kattan MW; Huland H
Urologe A; 2003 May; 42(5):685-92. PubMed ID: 12750804
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
16. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
Roach M; Weinberg V; Sandler H; Thompson I
Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
[TBL] [Abstract][Full Text] [Related]
17. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.
Spalding AC; Daignault S; Sandler HM; Shah RB; Pan CC; Ray ME
Urology; 2007 May; 69(5):936-40. PubMed ID: 17482938
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.
Chism DB; Hanlon AL; Horwitz EM; Feigenberg SJ; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):380-5. PubMed ID: 15145151
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
20. Primary cryoablation nadir prostate specific antigen and biochemical failure.
Levy DA; Pisters LL; Jones JS
J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]